SCHEMBL808500

SCHEMBL808500

O=Cc1c(-c2ccc3ccccc3c2C=O)ccc2ccccc12

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 3/20 0.64
MAPT P10636 3/20 0.53
CYP1A2 P05177 2/20 0.53
CYP2C9 P11712 2/20 0.53
CYP2C19 P33261 2/20 0.53
L3MBTL1 Q9Y468 2/20 0.50
NPC1 O15118 2/20 0.50
RAB9A P51151 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
TDP1 Q9NUW8 2/20 0.49
GAA P10253 1/20 0.49
ALDH1A1 P00352 3/20 0.48
HSD17B10 Q99714 2/20 0.48
CYP2A6 P11509 1/20 0.48
TSHR P16473 1/20 0.48
ADRB2 P07550 1/20 0.46
ADRB1 P08588 1/20 0.46
HPRT1 P00492 1/20 0.44
DNMT1 P26358 1/20 0.44
PADI4 Q9UM07 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29391032 1.00 ERN1 (0.64) ERN1MAPTCYP1A2CYP2C9CYP2C19
SCHEMBL3071898 0.88 ERN1 (0.56) ERN1MAPTCYP1A2CYP2C9CYP2C19
SCHEMBL23234176 0.87 ERN1 (0.51) ERN1MAPTCYP1A2CYP2C9CYP2C19
SCHEMBL249731 0.87 ERN1 (0.71) ERN1MAPTCYP1A2CYP2C9CYP2C19
SCHEMBL9153615 0.84 ERN1 (0.67) ERN1MAPTCYP1A2CYP2C9CYP2C19
SCHEMBL5002573 0.84 ERN1 (0.62) ERN1MAPTCYP1A2CYP2C9CYP2C19
SCHEMBL21223045 0.83 ERN1 (0.47) ERN1MAPTCYP1A2CYP2C9CYP2C19
SCHEMBL14643530 0.83 ERN1 (0.47) ERN1MAPTCYP1A2CYP2C9CYP2C19
SCHEMBL9856898 0.83 ERN1 (0.47) ERN1MAPTCYP1A2CYP2C9CYP2C19
SCHEMBL10898053 0.82 ERN1 (0.50) ERN1MAPTCYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1457482-B9 Stable isotope-labeled amino acid, method of integrating the same into target protein, method of NMR structural analysis of protein JAPAN SCIENCE & TECH AGENCY (JP) 2012-10-24 EP disclosed
EP-1457482-B1 Stable isotope-labeled amino acid, method of integrating the same into target protein, method of NMR structural analysis of protein JAPAN SCIENCE & TECH AGENCY (JP) 2012-01-18 EP disclosed
US-7022310-B2 Stable isotope-labeled amino acid and method for incorporating same into target protein AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2006-04-04 US disclosed
US-20050084452-A1 Stable isotope-labeled amino acid and method for incorporating same into target protein JAPANESE SCIENCE AND TECHNOLOGY AGENCY 2005-04-21 US disclosed
EP-1457482-A1 STABLE ISOTOPE-LABELED AMINO ACID, METHOD OF INTEGRATING THE SAME INTO TARGET PROTEIN, METHOD OF NMR STRUCTURAL ANALYSIS OF PROTEIN AND PROCESS FOR PRODUCING SITE-SELECTIVE STABLE ISOTOPE-LABELED FUMARIC ACID AND TARTARIC ACID Japan Science and Technology Agency (JP) 2004-09-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050084452-A1 Stable isotope-labeled amino acid and method for incorporating same into target protein GEMIN5, ATIC, AIP ERN1 3870/4885MAPT 3325/4885CYP1A2 4429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.